Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Assets (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Other Non-Current Assets data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 136.5% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 136.5%, while the annual FY2025 figure was $1.4 million, 136.5% up from the prior year.
  • Other Non-Current Assets reached $1.4 million in Q4 2025 per ARQT's latest filing, up from $596000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.5 million in Q1 2021 and bottomed at $78000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $879705.9, with a median of $900000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: soared 3180.85% in 2021, then crashed 94.94% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.5 million in 2021, then decreased by 22.18% to $1.2 million in 2022, then fell by 22.92% to $925000.0 in 2023, then crashed by 35.14% to $600000.0 in 2024, then skyrocketed by 136.5% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.4 million in Q4 2025, $596000.0 in Q3 2025, and $308000.0 in Q2 2025.